ERBB2 and neoplasm: This concept prompted the first-in-human clinical trial conducted by Klichinsky et al. who demonstrated that anti-HER2 CAR-M efficiently induced phagocytosis of the HER2+ ovarian SKOV3 tumor cells, pro-inflammatory cytokines secretion, macrophages polarization from M2 to M1 phenotype and were capable of cross-presenting the New York Esophageal Squamous cell carcinoma 1 (NY-ESO-1) antigen to T cells, following NY-ESO-1+ SKOV3 tumor cells phagocytosis [223].